Background Imipenem, a carbapenem antibiotic with a broader antimicrobial spectrum and greater potency than other beta-lactam antibiotics, has been considered a last-resort antibiotic for severe Gram-negative infections. However, escalating resistance now threatens its clinical utility worldwide. This review synthesizes current knowledge on the epidemiology, molecular mechanisms, and therapeutic challenges associated with imipenem resistance in clinically significant pathogens such as Klebsiella pneumoniae , Escherichia coli, Pseudomonas aeruginosa , and Acinetobacter baumannii . Resistance arises through diverse pathways—including carbapenemase production, porin loss, efflux pump overexpression, and synergistic mutations—that collectively diminish drug efficacy and complicate treatment. Methods A systematic literature search was conducted across four major electronic databases — PubMed, Scopus, ScienceDirect, and Google Scholar — to identify relevant publications on imipenem resistance, carbapenem resistance mechanisms, clinical outcomes, and antibiotic stewardship interventions. Sixty-six publications met the inclusion criteria. Results Therapeutic options remain limited, often relying on toxic or suboptimal agents such as colistin, while emerging alternatives—including β-lactam/β-lactamase inhibitor combinations, cefiderocol, antimicrobial peptides, bacteriophages, and immunomodulatory approaches—show promise but are not yet universally accessible. Effective management therefore requires integration of precision diagnostics, antimicrobial stewardship, and infection prevention strategies to optimize therapy and contain transmission. Conclusion Coordinated action across bedside practice, hospital policy, and global health governance is essential to preserve existing therapies and accelerate the development of sustainable alternatives. Without decisive intervention, the continued rise of imipenem resistance may herald a post-antibiotic era in which even routine infections become untreatable.